Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) announced on October 15th that Amber Hydroeight Amantadine tablet is a new, potent, and well-defined acetylcholinesterase inhibitor, a type 1 new drug with completely independent intellectual property rights and a new chemical molecular structure, used for the treatment of mild to moderate Alzheimer's disease.
Simultaneously, the main crystal form of Amber Hydroeight Amantadine has successively obtained international PCT (Patent Cooperation Treaty) protection, with Japan patent authorization obtained in September 2022. European authorization was obtained in May 2023, in specific countries including the United Kingdom, Germany, Swiss Franc, Sweden, the Netherlands, Denmark, Finland, Belgium, France, Austria, Spain, Norway, Ireland, Greece, and Italy. Patent authorization was obtained in the USA in September 2024. The main crystal form protection period for Amber Hydroeight Amantadine is twenty years (counted from the application date).
